This notification provides you, as a valued member of the Antipodes Emerging Markets (Managed Fund) (the Fund), with information about the upcoming changes to the Fund’s name, investable universe, benchmark and investment objective.
This is for your information only and you are not required to take any action.
The changes that took effect from 1 October 2022 are as follows:
| Old | New (from 1 October 2022) | |
|---|---|---|
| Fund Name | Antipodes Asia Fund | Antipodes Emerging Markets (Managed Fund) |
| Benchmark | MSCI All Country Asia ex Japan Index | MSCI Emerging Markets Index |
| Investment objective | The aim of the Fund is to achieve absolute returns in excess of the Benchmark over the investment cycle (typically 3-5 years) | The Fund aims to outperform the Benchmark over the investment cycle (typically 3-5 years) |
| Investable universe | The Fund typically invests in a select number of attractively valued companies listed on Asian-focused share markets | The Fund typically invests in a select number of attractively valued companies that are exposed to emerging markets or are listed on emerging stock exchanges |
| Short selling of equity securities permitted | Yes | No |
| Strategy | Long / short | Long only |
Background
Antipodes Partners Limited (Antipodes), the Fund’s investment manager, continuously reviews its offerings to ensure they continue to meet client requirements.
While the Fund has always had the flexibility to invest to up to 15% of its net exposure in non-Asia emerging markets, Antipodes believes the changes outlined in the table above will enhance its opportunities to generate attractive long-term returns.
There is no change to Antipodes’ team or investment process.
We appreciate your support and if you have any questions please contact our Client Services Team on 1300 010 311.